Alzheimer's disease biomarkers as outcome measures for clinical trials in MCI

BACKGROUND: Aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). METHODS: MRI, FDG-PET markers, and ADAS-COG were compared in terms of effect size and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimer Dis Assoc Disord
Main Authors: Caroli, Anna, Prestia, Annapaola, Wade, Sara, Chen, Kewei, Ayutyanont, Napatkamon, Landau, Susan M., Madison, Cindee M., Haense, Cathleen, Herholz, Karl, Reiman, Eric M., Jagust, William J., Frisoni, Giovanni B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4437812/
https://ncbi.nlm.nih.gov/pubmed/25437302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/WAD.0000000000000071
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados